Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,758 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Conditions
Locally Advanced or Metastatic and Unresectable HCC
Interventions
SHR-1210, Apatinib, Sorafenib
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Beverly Hills, California • La Jolla, California • Orange, California + 5 more
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Navitoclax, Osimertinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
cisplatin, ifosfamide, paclitaxel, vinblastine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
78
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Head and Neck Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Conditions
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Sapanisertib, Ziv-Aflibercept
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
31
States / cities
Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more
Conditions
Hepatocellular Carcinoma, Liver Neoplasms
Interventions
ThermoDox
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
Interventions
⁸⁹Zr-Df-IAB22M2C Infusion
Drug
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
Conditions
Advanced/Metastatic Solid Tumors
Interventions
NMS-03305293
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroendocrine Tumors
Interventions
fosbretabulin tromethamine
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab, SAbR
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Interventions
CF33-hNIS, Pembrolizumab, Modified FOLFOX
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more
Conditions
Non-small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Paclitaxel
Drug
Lead sponsor
Jeffrey Clarke
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Prostate Cancer
Interventions
Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires, Phone Call/Email
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8
Interventions
Carboplatin, Cemiplimab, Paclitaxel
Drug · Biological
Lead sponsor
Marcelo Bonomi
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Pembrolizumab
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Kenner, Louisiana • New Orleans, Louisiana
Conditions
Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions
ASP5834, panitumumab
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Costa Mesa, California • Orange, California • The Bronx, New York + 1 more